{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:59:27Z","timestamp":1794434367530,"version":"4.9.1"},"reference-count":71,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune\u2010related adverse events (cirAEs), including ICI\u2010induced eosinophilic fasciitis (ICI\u2010EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to further characterize the clinical features and outcomes of ICI\u2010EF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI\u2010EF cases from EADV Task Force\u2010affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow\u2010up data were extracted from the medical records and databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We present 121 ICI\u2010EF cases from the EADV Task Force (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915), FPVD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200921), VigiBase\u00ae (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945) and the literature (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD\u20101 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI\u2010EF onset was 10\u2009months (IQR 6.8\u201316.3; range\u2009&lt;\u20091\u201336). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI\u2010EF symptoms (66%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICI\u2010EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70512","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:51:26Z","timestamp":1780908686000},"page":"1702-1712","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitor\u2010induced eosinophilic fasciitis: A pharmacovigilance and\n                    <scp>EADV<\/scp>\n                    Task force study"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5931-0778","authenticated-orcid":false,"given":"Tristan V. M.","family":"Bruijn","sequence":"first","affiliation":[{"name":"Department of Dermatology Amsterdam UMC  Amsterdam The Netherlands"},{"name":"Department of Dermatology The Netherlands Cancer Institute\u2013Antoni Van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre O.","family":"G\u00e9rard","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Universit\u00e9 C\u00f4te d'Azur, University Hospital Centre of Nice  Nice France"},{"name":"Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, Universit\u00e9 C\u00f4te d'Azur  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblys","family":"Labat","sequence":"additional","affiliation":[{"name":"Saint Louis R\u00e9gional Pharmacovigilance Centre, Clinical Investigation Centre (INSERM CIC 1427), Saint\u2010Louis Hospital  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-8196","authenticated-orcid":false,"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[{"name":"Second Dermatology Department, School of Medicine, Faculty of Health Sciences Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter van","family":"Binsbergen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology &amp; Clinical Immunology Amsterdam UMC  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-2374","authenticated-orcid":false,"given":"Dimitra","family":"Koumaki","sequence":"additional","affiliation":[{"name":"Dermatology Department University Hospital of Heraklion  Crete Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerian","family":"Rivet","sequence":"additional","affiliation":[{"name":"Internal Medicine and Immunopathology Department The Cancer University of Toulouse Oncopole, Toulouse University Hospital  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-1042","authenticated-orcid":false,"given":"Frederic","family":"Dezoteux","sequence":"additional","affiliation":[{"name":"Service de Dermatologie H\u00f4pital Claude\u2010Huriez, Universit\u00e9 de Lille, INFINITE Institute for Translational Research in Inflammation  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Giacchero","sequence":"additional","affiliation":[{"name":"Oncology Departement Centre Antoine Lacassagne  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Ardern\u2010Jones","sequence":"additional","affiliation":[{"name":"Clinical Experimental Sciences, Faculty of Medicine University of Southampton  Southampton UK"},{"name":"Department of Dermatology University Hospitals Southampton NHS Foundation Trust  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Heelan","sequence":"additional","affiliation":[{"name":"The Royal Marsden Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse P.","family":"Hirner","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Nebraska  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-5995","authenticated-orcid":false,"given":"Ander","family":"Mayor","sequence":"additional","affiliation":[{"name":"Servicio de Dermatolog\u00eda Hospital Universitario La Paz  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette","family":"Labots","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Amsterdam UMC, Cancer Center Amsterdam  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Starink","sequence":"additional","affiliation":[{"name":"Department of Dermatology Amsterdam UMC  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny J. van der","family":"Laken","sequence":"additional","affiliation":[{"name":"Department of Rheumatology &amp; Clinical Immunology Amsterdam UMC  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[{"name":"Department of Oncodermatology Oncopole Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-2439","authenticated-orcid":false,"given":"Yannick S.","family":"Elshot","sequence":"additional","affiliation":[{"name":"Department of Dermatology Amsterdam UMC  Amsterdam The Netherlands"},{"name":"Department of Dermatology The Netherlands Cancer Institute\u2013Antoni Van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1001"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020259"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.015"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.001"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031982"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.030"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184450"},{"key":"e_1_2_14_12_1","volume-title":"National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1246-7820(99)80036-6"},{"key":"e_1_2_14_15_1","unstructured":"UMC V. Analytics in VigiLyze [Internet].https:\/\/www.whomc.org\/vigibase\/vigilyze\/analytics\u2010in\u2010vigilyze\/"},{"key":"e_1_2_14_16_1","unstructured":"MedDRA. MedDRA Hierarchy [Internet].https:\/\/www.meddra.org\/how\u2010to\u2010use\/basics\/hierarchy"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.6198"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex369"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.05.002"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223249"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14126"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0186"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12836"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.016"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez164"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/JIPO.JIPO_8_19"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0508"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa001"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.04.010"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00246-z"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.04.017"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.11.019"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X211025111"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.932888"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.32.4.376"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-21-19"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2023.07.001"},{"issue":"1","key":"e_1_2_14_41_1","article-title":"Moderate\u2010to\u2010severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion Q","year":"2020","journal-title":"Oncotargets and Therapy"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1078560"},{"issue":"1","key":"e_1_2_14_43_1","first-page":"1","article-title":"Musculoskeletal immune\u2010related adverse effects of immune checkpoint inhibitors at a single site in a Hispanic population in Puerto Rico","volume":"73","author":"Santiago AVS","year":"2021","journal-title":"Arthritis & Rhematology"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2021.4181"},{"issue":"2","key":"e_1_2_14_45_1","first-page":"182","article-title":"Immune checkpoint inhibitor\u2010induced eosinophilic fasciitis: a case report and literature review","volume":"62","author":"Ouyang ZM","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"e_1_2_14_46_1","first-page":"1","article-title":"Eosinophilic fasciitis 6 months after cessation of nivolumab","volume":"64","author":"Heddle G","year":"2023","journal-title":"The Australasian Journal of Dermatology"},{"issue":"2","key":"e_1_2_14_47_1","first-page":"171","article-title":"Eosinophilic fasciitis As an immune\u2010related adverse event of pembrolizumab in Hodgkin's lymphoma: a case report","volume":"16","author":"Khan K","year":"2024","journal-title":"Khyber Medical University Journal"},{"issue":"1","key":"e_1_2_14_48_1","first-page":"1","article-title":"Eosinofiele fasciitis na immuun checkpoint inhibitie met pembrolizumab","volume":"79","author":"Vanhees J","year":"2023","journal-title":"Tijdschrift voor Geneeskunde"},{"issue":"1","key":"e_1_2_14_49_1","first-page":"1","article-title":"P14 a rare adverse event of eosinophilic fasciitis secondary to immune checkpoint inhibitor therapy","volume":"7","author":"Byravan S","year":"2023","journal-title":"Rheumatol adv Pract"},{"issue":"1","key":"e_1_2_14_50_1","first-page":"1","article-title":"CPC11: immune checkpoint inhibitor\u2010associated eosinophilic fasciitis: a case report","volume":"188","author":"Ashraf M","year":"2023","journal-title":"The British Journal of Dermatology"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.027"},{"issue":"8","key":"e_1_2_14_52_1","article-title":"Nivolumab\u2010induced fasciitis mimicking scleroderma: a diagnostic challenge","volume":"17","author":"Jannat R","year":"2025","journal-title":"Cureus"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.948323"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2025.4825"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2024.03.006"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.019"},{"issue":"1","key":"e_1_2_14_57_1","first-page":"75","article-title":"Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis","volume":"28","author":"Viallard JF","year":"2001","journal-title":"The Journal of Rheumatology"},{"issue":"8","key":"e_1_2_14_58_1","first-page":"1811","article-title":"In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis","volume":"30","author":"Toquet C","year":"2003","journal-title":"The Journal of Rheumatology"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12947"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14160"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.01.011"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.301223.itr"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246151"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3648"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13770"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114172"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12499"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.089"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.004"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102681"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15747"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:29:02Z","timestamp":1790328542000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/jdv.70512"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70512","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}